Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-17	€0.0440	0.00%	121
26-08-14	€0.0440	-8.33%	0
26-08-13	€0.0480	0.00%	0
26-08-12	€0.0480	-3.03%	8,000
26-08-11	€0.0495	+6.45%	469

End-of-day quote Deutsche Boerse AG

More quotes

End-of-day quote Deutsche Boerse AG 2026-08-14			5-day change	1st Jan Change
0.0440 ^EUR	-8.33%		-5.38%	+233.33%

Market Cap	144K 167K 135K 123K 232K 15.96M 235K 1.58M 621K 8M 627K 613K 26.6M	P/E 2021	-3.89x	P/E 2022	-53x
Enterprise Value	9.87M 11.43M 9.26M 8.43M 15.85M 1.09B 16.07M 109M 42.52M 547M 42.91M 41.98M 1.82B	EV / Sales 2021	14.1x	EV / Sales 2022	1.22x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

1 day	-8.33%
1 week	-5.38%
Current month	-20.00%
1 month	-20.00%
3 months	-24.14%
6 months	-67.29%
Current year	+233.33%

1 week	0.04	0.05
1 month	0.04	0.06
Current year	0.01	0.23
1 year	0.01	0.23
3 years	0	5.57
5 years	0	20.15
10 years	0	36.78

Manager	Title	Age	Since
Tilmann Bur CEO	Chief Executive Officer	62	2023-08-31
Sebastian Werner DFI	Director of Finance/CFO	-	2022-05-31

Paion AG Stock

Stocks

PA8K

DE000A3E5EG5

Biotechnology & Medical Research

Valuation: Paion AG

Chart: Paion AG

Latest news : Paion AG

Press Releases: Paion AG

News in other languages: Paion AG

Quotes and Performance

Course Extremes

Managers and Directors: Paion AG

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Director	Title	Age	Since
Karin Louise Dorrepaal BRD	Director/Board Member	65	2012-09-30
Hans Tanner BRD	Director/Board Member	75	2017-05-31
Markus Guilherme Dieken BRD	Director/Board Member	-	2019-05-21

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/27/22	Gregor Siebert	Buy	Director	1,121	0.0016%
1/12/21	James Phillips	Buy	Chief Executive Officer	8,500	0.0127%
6/8/20	James Phillips	Buy	Chief Executive Officer	13,158	0.0202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PAION AG	-8.33%	-5.38%	+388.89%	-99.09%	364K
LONZA GROUP AG	+0.23%	-1.70%	+1.76%	+19.86%	48.84B
REVOLUTION MEDICINES, INC.	+4.07%	+2.43%	+483.70%	+623.80%	45.44B
BEONE MEDICINES AG	+4.33%	+0.98%	+12.80%	+88.53%	41.22B
IQVIA HOLDINGS INC.	+1.94%	-0.31%	+26.24%	+12.62%	39.71B
CELLTRION, INC.	-0.50%	0.00%	+20.60%	+60.49%	32.6B
ASCENDIS PHARMA A/S	+0.10%	-3.22%	-	-	16.25B
MEDPACE HOLDINGS, INC.	+3.22%	-0.88%	+30.42%	+135.47%	16.67B
EUROFINS SCIENTIFIC SE	-0.20%	-0.06%	+3.74%	+29.51%	14.08B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.35%	+3.48%	+82.95%	+43.41%	13.68B
Average	+0.72%	-0.52%	+116.79%	+101.62%	26.85B
Weighted average by Cap.	+1.93%	+0.03%	+103.08%	+153.44%

	2021	2022
Net sales	7.13M 8.26M 6.69M 6.09M 11.45M 789M 11.61M 78.4M 30.72M 396M 31M 30.33M 1.32B	33.25M 38.51M 31.19M 28.41M 53.42M 3.68B 54.16M 366M 143M 1.84B 145M 141M 6.14B
Net income	-21.79M -25.24M -20.44M -18.62M -35M -2.41B -35.49M -240M -93.89M -1.21B -94.74M -92.69M -4.02B	-579K -671K -543K -495K -930K -64.13M -943K -6.37M -2.5M -32.13M -2.52M -2.46M -107M
Net Debt	13.77M 15.95M 12.92M 11.77M 22.12M 1.52B 22.43M 151M 59.34M 764M 59.88M 58.58M 2.54B	9.72M 11.26M 9.12M 8.31M 15.62M 1.08B 15.84M 107M 41.9M 540M 42.28M 41.37M 1.79B